New England Journal of Medicine (NEJM) to Publish Results From Savaraâs Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase...
When can investors expect regulatory filing or FDA approval timelines based on these Phase 3 results, and what market size estimates support revenue forecasts?
What are the key efficacy and safety data points from the IMPALA-2 trial, and how do they compare to existing therapies for autoimmune PAP?
How will the publication of the Phase 3 IMPALA-2 results in NEJM affect Savara's stock valuation and shortâterm price movement?
6 days ago